Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

141. Interaction between Host MicroRNAs and the Gut Microbiota in Colorectal Cancer Full Text available with Trip Pro

Interaction between Host MicroRNAs and the Gut Microbiota in Colorectal Cancer Although variation in gut microbiome composition has been linked with colorectal cancer (CRC), the factors that mediate the interactions between CRC tumors and the microbiome are poorly understood. MicroRNAs (miRNAs) are known to regulate CRC progression and are associated with patient survival outcomes. In addition, recent studies suggested that host miRNAs can also regulate bacterial growth and influence (...) studies have found an association between colorectal cancer (CRC) and the gut microbiota. One potential mechanism by which the microbiota can influence host physiology is through affecting gene expression in host cells. MicroRNAs (miRNAs) are small noncoding RNA molecules that can regulate gene expression and have important roles in cancer development. Here, we investigated the link between the gut microbiota and the expression of miRNA in CRC. We found that dozens of miRNAs are differentially

2018 mSystems

142. Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis Full Text available with Trip Pro

Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis Colorectal cancer (CRC) is a common and lethal disease in which distant metastasis remains the primary cause of death. Paradoxical roles of LOX have been reported in CRC, and the intracellular function of LOX has also recently been determined. Correlations of LOX expression and its intracellular localization with clinicopathological features in CRC patients remain largely unknown. The aim of the present study (...) expression was correlated with synchronous or postoperative lung/hepatic metastasis. LOX may prove to be a potential target gene of YAP and TEAD4.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

143. Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence. Full Text available with Trip Pro

Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence. Individuals with adenomatous polyps are advised to undergo repeated colonoscopy surveillance to prevent subsequent colorectal cancer (CRC), but the relationship between adenomas at colonoscopy and long-term CRC incidence is unclear.To compare long-term CRC incidence by colonoscopy adenoma findings.Multicenter, prospective cohort study of participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO (...) -2.7], P = .68).Over a median of 13 years of follow-up, participants with an advanced adenoma at diagnostic colonoscopy prompted by a positive flexible sigmoidoscopy result were at significantly increased risk of developing colorectal cancer compared with those with no adenoma. Identification of nonadvanced adenoma may not be associated with increased colorectal cancer risk.clinicaltrials.gov Identifier: NCT00002540.

2018 JAMA Controlled trial quality: predicted high

144. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer Full Text available with Trip Pro

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) and has demonstrated efficacy in later lines. Progressive disease (PD) occurs when tumours develop resistance to a therapy, although controversy remains about whether PD

2018 ESMO open

145. Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and mortality in colorectal cancer surgery in England: population based cohort study. Full Text available with Trip Pro

Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and mortality in colorectal cancer surgery in England: population based cohort study. To determine the effect of surgeon specific outcome reporting in colorectal cancer surgery on risk averse clinical practice, "gaming" of clinical data, and 90 day postoperative mortality.National cohort study.English National Health Service hospital trusts.111 431 patients diagnosed as having colorectal cancer from 1 April 2011 (...) to 31 March 2015 included in the National Bowel Cancer Audit.Public reporting of surgeon specific 90 day mortality in elective colorectal cancer surgery in England introduced in June 2013.Proportion of patients with colorectal cancer who had an elective major resection, predicted 90 day mortality based on characteristics of patients and tumours, and observed 90 day mortality adjusted for differences in characteristics of patients and tumours, comparing patients who had surgery between April 2011

2018 BMJ

146. Colorectal Cancer Screening

Colorectal Cancer Screening Revised 2018 ACR Appropriateness Criteria ® 1 Colorectal Cancer Screening American College of Radiology ACR Appropriateness Criteria ® Colorectal Cancer Screening Variant 1: Colorectal cancer screening. Average-risk individual. Age greater than or equal to 50 years. Initial screening, then follow-up every 5 years after initial negative screen. Procedure Appropriateness Category Relative Radiation Level CT colonography Usually Appropriate ??? X-ray barium enema double (...) -contrast May Be Appropriate ??? MR colonography May Be Appropriate O X-ray barium enema single-contrast Usually Not Appropriate ??? Variant 2: Colorectal cancer screening. Moderate-risk individual. First-degree family history of cancer or adenoma. Initial screening, then follow-up every 5 years after initial negative screen. Procedure Appropriateness Category Relative Radiation Level CT colonography Usually Appropriate ??? X-ray barium enema double-contrast May Be Appropriate ??? MR colonography May

2018 American College of Radiology

147. Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies Full Text available with Trip Pro

Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies To systematically identify and validate published colorectal cancer risk prediction models that do not require invasive testing in two large population-based prospective cohorts.Models were identified through an update of a published systematic review and validated in the European (...) Prospective Investigation into Cancer and Nutrition (EPIC) and the UK Biobank. The performance of the models to predict the occurrence of colorectal cancer within 5 or 10 years after study enrolment was assessed by discrimination (C-statistic) and calibration (plots of observed vs predicted probability).The systematic review and its update identified 16 models from 8 publications (8 colorectal, 5 colon and 3 rectal). The number of participants included in each model validation ranged from 41 587 to 396

2018 EvidenceUpdates

148. Combination drug development in BRAF mutant colorectal cancer Full Text available with Trip Pro

Combination drug development in BRAF mutant colorectal cancer 29854866 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Combination drug development in BRAF mutant colorectal cancer. 51-53 10.18632/oncoscience.399 Lam Michael M Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University (...) of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, Texas 77030, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF mutant colorectal cancer ERK MEK combinations resistance CONFLICTS OF INTEREST The authors declare

2018 Oncoscience

149. Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer Full Text available with Trip Pro

Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer 29854868 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer. 57-58 10.18632/oncoscience.401 Gao Chenxi C Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Hu Jing J Department (...) of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF CRC FAK resistance the Wnt/b-catenin pathway CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 16 2018 04 16 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854868 10.18632/oncoscience.401 401 PMC5978442 Sci Signal. 2012 Jan 10;5(206):ra3 22234612 Proc Natl Acad

2018 Oncoscience

150. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se Full Text available with Trip Pro

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had

2018 ESMO open Controlled trial quality: uncertain

151. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Full Text available with Trip Pro

Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. The long-term effects of sigmoidoscopy screening on colorectal cancer (CRC) incidence and mortality in women and men are unclear.To determine the effectiveness of flexible sigmoidoscopy screening after 15 years of follow-up in women and men.Randomized controlled trial. (ClinicalTrials.gov: NCT00119912).Oslo and Telemark County, Norway.Adults aged 50 to 64 years (...) in women.Norwegian government and Norwegian Cancer Society.

2018 Annals of Internal Medicine Controlled trial quality: predicted high

152. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Volume 154, Issue 3, Pages 736–745.e14 Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations x Denis Hadjiliadis Affiliations Perelman School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania Correspondence Reprint (...) Institute of Oncology, Milan, Italy 5 , x Albert B. Lowenfels Affiliations New York Medical College, Valhalla, New York 6 on behalf of the x Cystic Fibrosis Colorectal Cancer Screening Task Force x Amy Leigh Braid x Amy Leigh Braid , x Joanne Cullina x Joanne Cullina , x Anne Daggett x Anne Daggett , x Aliza Fink x Aliza Fink , x Andrea Gini x Andrea Gini , x Denis Hadjiliadis x Denis Hadjiliadis , x Paul F. Harron x Paul F. Harron , x Sarah Hempstead x Sarah Hempstead , x Alexander Khoruts x Alexander

2018 Cystic Fibrosis Foundation

153. ColonFlag for identifying people at risk of colorectal cancer

ColonFlag for identifying people at risk of colorectal cancer ColonFlag for identifying people at risk of ColonFlag for identifying people at risk of colorectal cancer colorectal cancer Medtech innovation briefing Published: 12 April 2018 nice.org.uk/guidance/mib142 pathways Summary Summary The technology technology described in this briefing is ColonFlag. It uses routinely available datasets to help identify people who are at high risk of developing colorectal cancer. The inno innovativ vative (...) aspects e aspects are that ColonFlag uses so-called big data and machine learning methods. The intended place in ther place in therap apy y would be as an addition to current investigations, such as faecal immunochemical tests, to help identify people who may need referral for suspected colorectal cancer. The main points from the e main points from the evidence vidence summarised in this briefing are from 4 observational studies including nearly 3.5 million patient records. They show that ColonFlag

2018 National Institute for Health and Clinical Excellence - Advice

154. New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer (Abstract)

New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer Purpose We sought to determine the long-term risk of cardiovascular disease (CVD)-stroke and myocardial infarction-and congestive heart failure (CHF) in older patients with colorectal cancer, as well as to understand the roles that preexisting comorbidities and cancer therapy play in increasing this risk. Patients and Methods We evaluated individuals from the SEER-Medicare database with incident stage I (...) to III colorectal cancer at age older than 65 years between January 1, 2000, and December 31, 2011 (n = 72,408) and compared these patients with a matched cohort of Medicare patients without cancer (n = 72,408). Results Median age at diagnosis of colorectal cancer was 78 years (range, 66 years to 106 years), and median follow-up was 8 years since diagnosis. The 10-year cumulative incidence of new-onset CVD and CHF were 57.4% and 54.5% compared with 22% and 18% for control, respectively ( P < .001

2018 EvidenceUpdates

155. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) Full Text available with Trip Pro

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed with bevacizumab

2018 EvidenceUpdates

156. Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery Full Text available with Trip Pro

Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery Recommendations for surveillance after curative surgery for colorectal cancer (CRC) include a 1-year post-resection abdominal-pelvic computed tomography (CT) scan and optical colonoscopy (OC). CT colonography (CTC), when used in CRC screening, effectively identifies colorectal polyps ≥10 mm and cancers. We performed a prospective study to determine whether CTC, concurrent with CT, could substitute (...) for OC in CRC surveillance.Our study enrolled 231 patients with resected stage 0-III CRC, identified at 5 tertiary care academic centers. Approximately 1 year after surgery, participants underwent outpatient CTC plus CT, followed by same-day OC. CTC results were revealed after endoscopic visualization of sequential colonic segments, which were re-examined for discordant findings. The primary outcome was performance of CTC in the detection of colorectal adenomas and cancers using endoscopy

2018 EvidenceUpdates

157. Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer Full Text available with Trip Pro

Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer Previous studies reported that black vs white disparities in survival among elderly patients with colorectal cancer (CRC) were because of differences in tumor characteristics (tumor stage, grade, nodal status, and comorbidity) rather than differences in treatment. We sought to determine the contribution of differences in insurance, comorbidities, tumor characteristics, and treatment receipt (...) to disparities in black vs white patients with CRC 18-64 years old.We used data from the National Cancer Database, a hospital-based cancer registry database sponsored by the American College of Surgeons and the American Cancer Society, on non-Hispanic black (black) and non-Hispanic white (white) patients, 18-64 years old, diagnosed from 2004 through 2012 with single or first primary invasive stage I-IV CRC. Each black patient was matched, based on demographic, insurance, comorbidity, tumor, and treatment

2018 EvidenceUpdates

158. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 Full Text available with Trip Pro

Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment (...) and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient. Each combination must seek to be effective and to generate the minimum adverse effects as possible. Instead of giving the first-line regimen until the tumour progresses, treatment is often individualised. Furthermore, up to 60

2018 ESMO open

159. Improving Internal Medicine Residents’ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study Full Text available with Trip Pro

Improving Internal Medicine Residents’ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer death in the United States. About one in three adults in the United States is not getting the CRC screening as recommended. Internal medicine residents are deficient in CRC screening knowledge.The objective of our study was to assess the improvement in internal medicine residents (...) ' CRC screening knowledge via a pilot approach using a smartphone app.We designed a questionnaire based on the CRC screening guidelines of the American Cancer Society, American College of Gastroenterology, and US Preventive Services Task Force. We emailed the questionnaire via a SurveyMonkey link to all the residents of an internal medicine department to assess their knowledge of CRC screening guidelines. Then we designed an educational intervention in the form of a smartphone app containing all

2018 JMIR medical education

160. Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Full Text available with Trip Pro

Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Screening for colorectal cancer (CRC) reduces mortality, yet more than one third of age-eligible Americans are unscreened.To examine the effect of a digital health intervention, Mobile Patient Technology for Health-CRC (mPATH-CRC), on rates of CRC screening.Randomized clinical trial. (ClinicalTrials.gov: NCT02088333).6 community-based primary care practices (...) to be screened within 6 months, discussed screening with their provider, and had a screening test ordered. Half of mPATH-CRC participants (53%; 118 of 223) "self-ordered" a test via the program.Participants were English speakers in a single health care system.A digital health intervention that allows patients to self-order tests can increase CRC screening. Future research should identify methods for implementing similar interventions in clinical care.National Cancer Institute.

2018 Annals of Internal Medicine Controlled trial quality: predicted high